Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IDENTIFICATION OF THE INHIBITORY P40 SUBUNIT OF INTERLEUKIN-12 FROM THE ASCITIC FLUID OF PATIENTS WITH ADVANCED-CARCINOMA OF THE OVARY
Autore:
DECESARE SL; GAMERO A; BECKER T; BARTON D; BOMALASKI J; FIORICA J; ARANGO H; HOFFMAN M; DJEU J;
Indirizzi:
SACRED HEART HOSP,5147 N 9TH AVE,SUITE 100 PENSACOLA FL 32504 UNIV FLORIDA,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL PENSACOLA FL 32504 UNIV S FLORIDA,DEPT OBSTET & GYNECOL TAMPA FL 33601 UNIV S FLORIDA,DEPT BIOCHEM TAMPA FL 33601 ROYAL MARSDEN NHS TRUST LONDON SW3 6JJ ENGLAND
Titolo Testata:
International journal of gynecological cancer
fascicolo: 2, volume: 8, anno: 1998,
pagine: 133 - 137
SICI:
1048-891X(1998)8:2<133:IOTIPS>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED HUMAN LYMPHOBLASTS; CELL STIMULATORY FACTOR; GROWTH-FACTOR-BETA; IL-12 RECEPTOR; BIOLOGIC ACTIVITY; KILLER-CELLS; CANCER; LYMPHOCYTES; RESPONSES; SYNERGIZES;
Keywords:
ASCITES; INTERLEUKIN-12; OVARIAN CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
S.L. Decesare et al., "IDENTIFICATION OF THE INHIBITORY P40 SUBUNIT OF INTERLEUKIN-12 FROM THE ASCITIC FLUID OF PATIENTS WITH ADVANCED-CARCINOMA OF THE OVARY", International journal of gynecological cancer, 8(2), 1998, pp. 133-137

Abstract

Objective: To determine the levels of interleukin 12 (IL-12) in the ascites from patients diagnosed with advanced epithelial ovarian cancer. Methods: Ascites samples from advanced ovarian cancer patients and peritoneal fluid from normal controls and endometriosis patients were tested for the presence of IL-12 by ELISA. Two different IL-12 ELISA kits were used. One ELISA kit detected the bioactive heterodimeric form of the IL-12 cytokine composed of the p40 and p35 subunits, while the second kit detected both the bioactive form and the p40 subunit of IL-12. Results: The first ELISA, which tested for only the bioactive heterodimer of IL-12, was negative in all 28 ovarian cancer patients. The second ELISA assay, which reacts with both the p40 subunit monomer andthe heterodimer of IL-12, showed detectable levels of IL-12 in all 28cancer patients and all 29 benign patients. Since no IL-12 heterodimer was detected in the first assay, these results represented the p40 monomer levels. A significantly higher median level of IL-12 monomer was found in malignant ascites compared to all benign control groups (P < 0.05). Conclusions: Ascites from advanced ovarian cancer patients contains significantly higher levels of the IL-12 p40 subunit than peritoneal fluid from normal patients, but contains no measurable bioactiveIL-12 heterodimer. The secreted p40 subunit has been shown to inhibitIL-12 mediated activation of T and natural killer cells in vitro. In vivo suppression of lymphocytes by IL-12 p40 in ovarian cancer patients has not yet been demonstrated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 03:44:38